ClinicalTrials.gg
CompletedNCT00295061ChAMPUpdated Sep 9, 2014Results posted

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

A Phase 3 interventional study of Alpha-1 MP and alpha-1 proteinase inhibitor (human) in Alpha 1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
14th of 25
24 · median 30
Started
2006
with 3 others
Phase 3
7 of 25
1 open now
Registered
3rd of 25
by date
Lead sponsor
10 of 25
Grifols Therapeutics LLC

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 14th largest by enrollment, is one of 4 that started in 2006, is one of 7 in phase 3, and was the 3rd registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP) and Prolastin in adult Alpha1-antitrypsin deficient patients. Patients will be infused intravenously with study drug on a weekly schedule for 24 weeks.

Read the detailed description

The objective of this study is to demonstrate the pharmacokinetic comparability of Alpha-1 MP to Prolastin® in subjects with Alpha1-antitrypsin deficiency.

This study is divided into three 8-week treatment sequences including an initial 8-week double-blind treatment period (with one of the 2 study drugs), a second 8-week double-blind treatment period (with the other study drug), and a third 8-week open-label treatment period (with Alpha-1 MP).

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency

Keywords

  • alpha 1-Antitrypsin Deficiency
  • alpha 1-Antitrypsin
  • pulmonary emphysema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of congenital Alpha1-antitrypsin deficiency
  • Must be receiving augmentation therapy with plasma-derived (human) Alpha1-Proteinase Inhibitor (Prolastin®) for at least one month prior to study entry.
  • Signed written prior to initiation of any study related procedures

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breast feeding, or if of , unwilling to practice adequate throughout the study
  • Use of systemic within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).
  • Subjects who have had exacerbations of their disease within one month of trial entry.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1 Alpha-1 MP

    Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP

    Drug: Alpha-1 MP

  • Active comparator
    2 Prolastin

    Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP

    Drug: alpha-1 proteinase inhibitor (human)

Interventions

  • alpha-1 proteinase inhibitor (human), 60 mg/kg body weight

    Also known as: Alpha-1 antitrypsin (AAT), TAL6004

  • Prolastin

    Also known as: Alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007

06

What researchers measure

Primary outcomes

  1. Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7

    The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being "bioequivalent" between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase.

    Time frame: Day 0 to Day 7

07

Results

Posted Sep 9, 2014

Participant flow

First-subject-first-dose was on 22 May 2006, Last-subject-last-visit was on 28 Feb 2007. The trial was performed at 6 clinical sites in the United States.

Participant flow — Overall Study
MilestoneAlpha-1 MP / ProlastinProlastin / Alpha-1 MP
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryAlpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7

The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being "bioequivalent" between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase.

Time frame:
Day 0 to Day 7
Reported as:
Number · mg*h/mL
Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7
mg*h/mLAlpha-1 MPProlastin
Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7155.9 (0.97 to 1.09)152.4 (0.97 to 1.09)
Statistical analysis
  • Alpha-1 MP vs Prolastin · Geometric least square means ratio: 1.03 · 90% CI 0.97 to 1.09

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1 MP—0/24 (0%)3/24 (12.5%)
Prolastin—1/24 (4.2%)5/24 (20.8%)
Most frequent serious events
Most frequent serious events
EventAlpha-1 MPProlastin
Cervical spinal stenosisMusculoskeletal and connective tissue disorders0/241/24
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/241/24
Most frequent other events
Most frequent other events
EventAlpha-1 MPProlastin
Upper respiratory tract infectionInfections and infestations2/241/24
ArthralgiaMusculoskeletal and connective tissue disorders0/242/24
HeadacheNervous system disorders1/242/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Alpha-1 MP / ProlastinProlastin / Alpha-1 MPTotal
<=18 years000
Between 18 and 65 years101020
>=65 years224
Age, Continuous
Age, Continuous(years)Alpha-1 MP / ProlastinProlastin / Alpha-1 MPTotal
Mean58.4 ± 6.8657.0 ± 9.3357.7 ± 8.04
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1 MP / ProlastinProlastin / Alpha-1 MPTotal
Female6814
Male6410
Region of Enrollment
Region of Enrollment(participants)Alpha-1 MP / ProlastinProlastin / Alpha-1 MPTotal
United States121224
08

Study locations

8 sites
  • National Jewish Medical and Research Center
    Denver, Colorado 80206, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610-0225, United States
  • University of Miami School of Medicine
    Miami, Florida 33101, United States
  • St Lukes-Roosevelt Hospital Center, New York
    New York, New York 10019, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44122, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas Health Center at Tyler
    Tyler, Texas 75708-3154, United States
09

References and documents

Publications

  • Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Sandhaus RA, Strange C, Turino G. Pharmacokinetic comparability of Prolastin(R)-C to Prolastin(R) in alpha(1)-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol. 2010 Sep 30;10:13. doi: 10.1186/1472-6904-10-13. PubMed 20920295 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2006
First posted
Feb 22, 2006
Start
May 2006
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Sep 9, 2014
Last update
Sep 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00295061
First posted
Feb 22, 2006
Start date
May 2006
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Sep 9, 2014
Last update
Sep 9, 2014

Study contacts

Kim Hanna, MSc
study director · Grifols Therapeutics LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion